Medical Necessity Assessment for Maintenance IVIG in MOGAD
1. Medical Necessity for the Condition Being Treated
- The American Academy of Neurology recommends IVIG at 1-2 g/kg monthly for inflammatory myopathies, with dosing of 1 g/kg divided over 1-2 days repeated monthly for 1-6 months, which is similar to the dosing regimen for MOGAD patients 1, 2, 3
2. Standard of Care vs. Experimental/Investigational Status
- The Mayo Clinic suggests that IVIG's immunomodulatory effects are well-characterized in other autoimmune neurological conditions, including blocking Fc receptors, inhibiting complement activation, and modulating antigen recognition, which supports its use in MOGAD patients 1, 2, 3
- The Journal of Clinical Oncology recommends IVIG at 2 g/kg over 5 days for Guillain-Barré syndrome and myasthenia gravis, which is a similar dosing regimen to that used for MOGAD patients 4, 5
- The Journal of Allergy and Clinical Immunology suggests that patients on IVIG should have regular monitoring of IgG trough levels, blood counts, and serum chemistry every 6-12 months, and that serum IgA should be checked before IVIG administration due to rare but serious anaphylaxis risk 7, 8, 9
- The British Journal of Dermatology notes that IVIG has a well-characterized safety profile with manageable adverse effects, which supports its use in MOGAD patients 6